...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: News Release

https://ceo.ca/@nasdaq/study-demonstrates-resverlogixs-apabetalone-treatment

 

Study Demonstrates Resverlogix’s Apabetalone Treatment Significantly Improves Cognition and Reduces Cognitive Decline Among Patients with Both Cardiovascular Disease and Diabetes Mellitus
    

Positive Findings in Journal of Alzheimer's Disease Suggest BET Inhibitor Apabetalone Holds Promise as a Safe and Effective Therapeutic for Vascular Cognitive Impairment

Apabetalone is a First-in-Class Oral Epigenetic Therapeutic Candidate which Positively Regulates and Normalizes Genes that Cause Chronic Illness

CALGARY, Alberta, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX), a world leader in epigenetics, or gene regulation, announces today new data that demonstrates their first-in-class oral small molecule BET inhibitor candidate Apabetalone significantly improves cognition and reduces cognitive decline among high-risk patients with cardiovascular disease (CVD) and diabetes mellitus.

The study findings were published in the peer-reviewed Journal of Alzheimer's Disease, titled: “Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified MoCA Analysis Nested in the BETonMACE Randomized Controlled Trial.” The Journal of Alzheimer's Disease study can be viewed HERE.

These findings suggest that the BET inhibitor Apabetalone holds promise as a safe and effective therapeutic avenue for vascular cognitive impairment. Apabetalone, an epigenetic therapeutic, is the first-in-class oral investigational BET inhibitor which positively regulates and normalizes genes that cause chronic illness.

These findings are a sub-study of the previously published BETonMACE cardiovascular disease (CVD) outcome study. Previously reported BETonMACE study details can be found using the following LINK.

“The exploratory pre-specified cognition analysis of BETonMACE suggests that Apabetalone represents a promising new therapeutic approach for patients with vascular cognitive impairment,” said Dr. Jeffrey L. Cummings, Vice Chair of Research, University of Nevada, Las Vegas, Department of Brain Health, and the lead author of the new peer-reviewed study. “A large unmet need remains in this population and finding safe and effective ways to prevent, or reverse cognitive decline is a global research priority,” further stated Dr. Cummings.

“Our interpretation is that favorable vascular effects in the brain tissue treated with apabetalone translates to improved cognition, which we had anticipated,” stated Donald McCaffrey, President and Chief Executive Officer. “We were extremely pleased to see that the effect was found in the group that needed it the most – those with cognitive impairment at the start of the study, thus adding a distinct treatment bonus effect to the CVD patients with diabetes,” Mr. McCaffrey continued.

Study Highlights and Conclusion:

  • In patients with baseline MoCA score ≤ 21, indicating cognitive impairment, Apabetalone treatment resulted in a significant 2.1 unit increase in MoCA score (p=0.02) – a clinically meaningful improvement when compared with the placebo group.
  • Alkaline phosphatase (ALP), a biomarker whose abundance is associated with cognitive decline, was reduced in the Apabetalone-treated group, relative to placebo (p=0.03).
  • This analysis highlights the continuing unmet need for treatment options for vascular cognitive impairment in high-risk cardiovascular patients with diabetes. The Apabetalone associated improvement in MoCA scores suggests that BET inhibition holds promise as a safe and effective therapeutic avenue for vascular cognitive impairment.

Study Background:

  • Risk of vascular cognitive impairment increases with age, cardiovascular disease (CVD), diabetes, and chronic kidney disease.
  • The effect of apabetalone treatment on cognition in a high-risk diabetic and CVD population was investigated in a prespecified analysis of the placebo controlled BETonMACE trial.
  • Patients 70 years and older (464 patients) were administered the Montreal Cognitive Assessment (MoCA) at baseline and yearly to monitor changes in cognition.

 

Share
New Message
Please login to post a reply